StockData
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd (HCM) stock

HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026Score 5/30
$14.40−0.33 (-2.24%)

Close on Nov 17, 2026Market cap $2.51BP/E 5.5Yield –

HUTCHMED (China) r&d expenses

Research and development expenses are spending on new products and technology.

HUTCHMED (China)'s R&D Expenses for the twelve months ending Dec 31, 2019 was $138.19M, up 21.0% year over year. For fiscal 2025 it was $148.30M, down 30.1% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $386.89M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$148.30M-30.1%
FY2024Dec 31, 2024$212.11M-29.8%
FY2023Dec 31, 2023$302.00M-21.9%
FY2022Dec 31, 2022$386.89M+29.4%
FY2021Dec 31, 2021$299.09M+71.1%
FY2020Dec 31, 2020$174.78M+26.5%
FY2019Dec 31, 2019$138.19M+21.0%
FY2018Dec 31, 2018$114.16M+51.2%
FY2017Dec 31, 2017$75.52M+12.9%
FY2016Dec 31, 2016$66.87M+41.2%
FY2015Dec 31, 2015$47.37M+58.3%
FY2014Dec 31, 2014$29.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019$37.46M+47.3%
Q3 FY2019Sep 30, 2019$31.45M+9.7%
Q2 FY2019Jun 30, 2019$36.01M+14.7%
Q1 FY2019Mar 31, 2019$33.28M+16.1%
Q4 FY2018Dec 31, 2018$25.43M–
Q3 FY2018Sep 30, 2018$28.68M–
Q2 FY2018Jun 30, 2018$31.39M–
Q1 FY2018Mar 31, 2018$28.66M–

More HUTCHMED (China) figures

See a number that looks wrong?